Chemotherapy and Targeted Therapy

From Pandemic Giant to Oncology Pioneer: BioNTech’s High-Stakes Pivot

• Chemotherapy and Targeted Therapy

From Pandemic Giant to Oncology Pioneer: BioNTech’s High-Stakes Pivot

Lina Hope June 16, 2026

In the annals of biotechnology, few companies have experienced a rise as meteoric—or a transition as jarring—as...

Read More Read more about From Pandemic Giant to Oncology Pioneer: BioNTech’s High-Stakes Pivot

Bridging the Gap: Mastering the Strategic Pivot from Lab to Clinic for Injectable Drugs

• Chemotherapy and Targeted Therapy

Bridging the Gap: Mastering the Strategic Pivot from Lab to Clinic for Injectable Drugs

Ali Ikhwan June 16, 2026

For biopharmaceutical developers, the moment an injectable molecule moves from the laboratory bench to the clinical trial...

Read More Read more about Bridging the Gap: Mastering the Strategic Pivot from Lab to Clinic for Injectable Drugs

Protecting Innovation in a Borderless Pharma Economy: The New Frontier of Globalized IP Strategy

• Chemotherapy and Targeted Therapy

Protecting Innovation in a Borderless Pharma Economy: The New Frontier of Globalized IP Strategy

Nila Kartika Wati June 16, 2026

In the modern pharmaceutical landscape, the journey of a drug from a laboratory bench to a patient’s...

Read More Read more about Protecting Innovation in a Borderless Pharma Economy: The New Frontier of Globalized IP Strategy

Eli Lilly’s New Myelofibrosis Candidate Challenges Incyte’s Dominance

• Chemotherapy and Targeted Therapy

Eli Lilly’s New Myelofibrosis Candidate Challenges Incyte’s Dominance

Nila Kartika Wati June 15, 2026

By Jacob Bell | June 15, 2026 Eli Lilly’s strategic bet on the biotech startup Ajax Therapeutics...

Read More Read more about Eli Lilly’s New Myelofibrosis Candidate Challenges Incyte’s Dominance

FDA Commissioner Marty Makary Resigns Amidst Administrative Pressure and Policy Turmoil

• Chemotherapy and Targeted Therapy

FDA Commissioner Marty Makary Resigns Amidst Administrative Pressure and Policy Turmoil

Iffa Jayyana June 15, 2026

WASHINGTON, D.C. — In a development that signals a profound shift in the regulatory landscape of the...

Read More Read more about FDA Commissioner Marty Makary Resigns Amidst Administrative Pressure and Policy Turmoil

Beyond the Plate: The Evolving Landscape of Celiac Disease Therapy

• Chemotherapy and Targeted Therapy

Beyond the Plate: The Evolving Landscape of Celiac Disease Therapy

Lina Irawan June 15, 2026

For the estimated one in 100 people worldwide living with celiac disease, the diagnosis is not merely...

Read More Read more about Beyond the Plate: The Evolving Landscape of Celiac Disease Therapy

The Paradox of Progress: Why Pharmaceutical Sustainability Goals Are Struggling Against Rising Emissions

• Chemotherapy and Targeted Therapy

The Paradox of Progress: Why Pharmaceutical Sustainability Goals Are Struggling Against Rising Emissions

Neng Nana June 15, 2026

The global healthcare sector, long viewed as a bastion of wellness and life-saving innovation, is confronting an...

Read More Read more about The Paradox of Progress: Why Pharmaceutical Sustainability Goals Are Struggling Against Rising Emissions

Bridging the Gap: How Novel Immune Therapies Are Reshaping the Treatment of TBI and Alzheimer’s Disease

• Chemotherapy and Targeted Therapy

Bridging the Gap: How Novel Immune Therapies Are Reshaping the Treatment of TBI and Alzheimer’s Disease

Azzam Bilal Chamdy June 15, 2026

Traumatic brain injury (TBI) is not merely a singular event—it is a chronic, often progressive condition that...

Read More Read more about Bridging the Gap: How Novel Immune Therapies Are Reshaping the Treatment of TBI and Alzheimer’s Disease

Biopharma Industry Update: AstraZeneca’s GLP-1 Ambitions and Strategic Shifts Across the Sector

• Chemotherapy and Targeted Therapy

Biopharma Industry Update: AstraZeneca’s GLP-1 Ambitions and Strategic Shifts Across the Sector

Raul Delapena Setiawan June 15, 2026

The global biopharmaceutical landscape continues to undergo rapid transformation, characterized by aggressive pursuits in metabolic health, cutting-edge...

Read More Read more about Biopharma Industry Update: AstraZeneca’s GLP-1 Ambitions and Strategic Shifts Across the Sector

The Double-Edged Sword of Retatrutide: Eli Lilly’s Newest Weight Loss Frontier

• Chemotherapy and Targeted Therapy

The Double-Edged Sword of Retatrutide: Eli Lilly’s Newest Weight Loss Frontier

Rifan Muazin June 15, 2026

The landscape of obesity treatment is undergoing a seismic shift. Eli Lilly, already a dominant force in...

Read More Read more about The Double-Edged Sword of Retatrutide: Eli Lilly’s Newest Weight Loss Frontier